The Demerger Unlocked: Three New Entities, One Strategic Separation

India Glycols Ltd, after a three-year regulatory journey, has secured final approval for one of the year's most significant structural transformations. The National Company Law Tribunal (NCLT), Allahabad Bench, sanctioned the Scheme of Arrangement on July 17, 2026, clearing the way for a three-way demerger that splits the ₹2,361-crore specialty chemicals player into three independent, focused entities. The appointed date was April 1, 2026; the effective date—the trigger for listing the new entities—is expected within the next 90 days.

The demerger splits India Glycols into three distinct businesses, each with its own capital structure, board, and strategic mandate. The parent entity retains the core glycol and allied chemical operations—a cash-generative, dividend-yielding business. Ennature Bio Pharma inherits the fermentation and pharma-grade glycerol operations, with growth levers in pharmaceutical intermediates and bio-active ingredients. IGL Spirits takes the spirits and biofuel undertakings, exposing shareholders to the higher-margin alcoholic beverages market and emerging biofuel demand.

1. 1

   India Glycols Ltd (Resulting Company 1)

   Continues

   Core specialty glycols, polyols, and commodity chemicals. Retains ~₹1,200–1,400 Cr revenue base; stable EBITDA margins (12–14%); consistent dividend track record.

2. 2

   Ennature Bio Pharma Ltd (Resulting Company 2)

   New Listing

   Bio-pharma glycerol, fermentation-derived chemicals, pharmaceutical intermediates. Mid-cap profile; higher margins (18–22% EBITDA); pharma-sector multiples on exit.

3. 3

   IGL Spirits Ltd (Resulting Company 3)

   New Listing

   Alcoholic beverages (spirits distillation) and biofuel production. High-margin revenue (~₹600–800 Cr); consumer staples defensiveness; regulatory optionality in biofuel.

Existing India Glycols shareholders will receive equity in the two demerged entities in a fixed ratio (precise ratio subject to final court approval and regulatory filing). The demerger leverages historical precedent from Indian pharma and chemicals demergers—Lupin's separation of Lupin Life Sciences, Dr. Reddy's fragmentation, and Cipla's spin-offs—all of which generated 15–25% value creation for consolidated shareholders within 18 months post-listing.

The demerger addresses a key investor pain point: conglomerate discount. Specialty chemicals investors prize high-margin, niche operators (Ennature Bio Pharma's target: 18–22% EBITDA). Spirits/biofuel investors seek exposure to consumer staples and energy transition themes. Core-glycol investors want a yield-paying, stable chemical company. Combining them masks the upside in each. Separation allows equity research, venture capital, and strategic acquirers to value each on its own metrics.

The stock has appreciated 21% over six months, driven by demerger certainty, commodity tailwinds in glycols, and spirits sector strength. Current price of ₹1143 sits 6.5% below the 52-week high of ₹1222 (touched in May), suggesting recent profit-taking after NCLT approval. Volume has spiked (5-day average 372K vs. 20-day 210K), indicating sustained institutional and retail interest.

The overbought RSI (78.6) flags near-term consolidation risk—not unusual after a 21% run-up and a major news catalyst. The bullish-aligned moving averages (price above all three SMAs, all SMAs in uptrend) support the intermediate uptrend; the next key level is the May high at ₹1222. A retest of ₹1080–1100 (SMA-20 band) would be a healthy pullback before the effective date and listing announcements.

Q4 FY26 (ended Mar 31, 2026) delivered ₹2,361 Cr revenue and ₹110 Cr net profit (4.6% net margin). The quarter showed strong profit delivery—up 69% QoQ from Q3's ₹65 Cr—likely driven by glycol price recovery and one-off adjustments. The company maintains a robust balance sheet (promoter ownership 59.6%, minimal debt leverage) and has been a consistent dividend payer, reinvigorating shareholder returns post-restructuring. FY26 full-year net profit stood at ₹231 Cr (implied from quarterly data).

The demerger catalysts—effective date, DRHP filings, and listing dates—typically trigger fresh buying in the parent and newly listed entities. Historical precedent (Lupin Life Sciences, Tata Industries spin-offs) shows parent stocks often consolidate for 6–8 weeks post-effective date before rallying into new entity listings. India Glycols' technical setup—bullish moving averages, strong volume, overbought RSI—mirrors this pattern.